EVM
DXCM icon

Eaton Vance Management’s DexCom DXCM Stock Holding History

Eaton Vance Management’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$66.6M Sell
826,977
-30,017
-4% -$2.54M 0.1% 208
2022
Q2 		$63.9M Buy
856,994
+228,294
+36% +$20.8M 0.09% 218
2022
Q1 		$80.4M Buy
628,700
+87,044
+16% +$9.52M 0.09% 215
2021
Q4 		$72.7M Buy
541,656
+17,096
+3% +$2.46M 0.09% 227
2021
Q3 		$71.1M Buy
524,560
+2,496
+0.5% +$315K 0.1% 200
2021
Q2 		$55.7M Buy
522,064
+5,556
+1% +$534K 0.08% 249
2021
Q1 		$46.4M Buy
516,508
+122,416
+31% +$11.5M 0.07% 272
2020
Q4 		$36.4M Buy
394,092
+788
+0.2% +$70.4K 0.06% 308
2020
Q3 		$40.5M Buy
393,304
+84
+0% +$8.78K 0.07% 241
2020
Q2 		$39.9M Sell
393,220
-152
-0% -$13.6K 0.08% 223
2020
Q1 		$26.5M Buy
393,372
+1,752
+0.4% +$109K 0.06% 252
2019
Q4 		$21.4M Buy
391,620
+176
+0% +$8.35K 0.04% 318
2019
Q3 		$14.6M Buy
391,444
+88
+0% +$3.42K 0.03% 367
2019
Q2 		$14.7M Buy
391,356
+500
+0.1% +$15.7K 0.03% 358
2019
Q1 		$11.6M Hold
390,856
– – 0.03% 386
2018
Q4 		$11.7M Buy
390,856
+11,008
+3% +$349K 0.03% 338
2018
Q3 		$13.6M Hold
379,848
– – 0.03% 350
2018
Q2 		$9.02M Sell
379,848
-379,848
-50% -$8.05M 0.02% 418
2018
Q1 		$14.1M Buy
759,696
+379,848
+100% +$5.62M 0.02% 446
2017
Q4 		$5.45M Hold
379,848
– – 0.01% 503
2017
Q3 		$4.65M Buy
379,848
+101,680
+37% +$1.8M 0.01% 518
2017
Q2 		$5.09M Hold
278,168
– – 0.01% 496
2017
Q1 		$5.89M Sell
278,168
-212
-0.1% -$4.14K 0.02% 449
2016
Q4 		$4.16M Buy
278,380
+212
+0.1% +$3.76K 0.01% 469
2016
Q3 		$6.1M Buy
278,168
+69,012
+33% +$1.54M 0.02% 384
2016
Q2 		$4.15M Buy
209,156
+100,000
+92% +$1.7M 0.01% 446
2016
Q1 		$1.85M Hold
109,156
– – 0.01% 564
2015
Q4 		$2.23M Hold
109,156
– – 0.01% 544
2015
Q3 		$2.34M Buy
+109,156
New +$2.44M 0.01% 523

Other funds holding DXCM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Eaton Vance Management's DXCM Position: Q3 2022 in Review

Eaton Vance Management reduced its DexCom (DXCM) stake by 3.5% in Q3 2022, selling an estimated $2.54M and leaving 826,977 shares worth $66.6M. The position accounts for 0.1% of the portfolio, ranked #208.

Eaton Vance Management first reported a position in DXCM in Q3 2015 and has held it in 29 quarters since. The position peaked at $80.4M in Q1 2022. 794 funds tracked by Wall St. Rank hold DXCM as of Q3 2022.

  • Eaton Vance Management held 826,977 shares of DexCom worth $66.6M as of Q3 2022.
  • Eaton Vance Management sold 30,017 DexCom shares in Q3 2022, an estimated $2.54M.
  • DexCom made up 0.1% of Eaton Vance Management's portfolio in Q3 2022, its #208 holding.
  • Eaton Vance Management first reported a position in DexCom in Q3 2015 and has held it in 29 quarters since.
  • Eaton Vance Management's DexCom position peaked at $80.4M in Q1 2022.
  • 794 funds tracked by Wall St. Rank held DexCom as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.